Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)

• The first study of its kind on incretin-based therapy together with MDI therapy. • The majority of the studied patient group can be found in primary care settings. • Glycaemic variability will be evaluated by masked continuous glucose monitoring.